Celecoxib and Prostaglandin E2 Levels in High-Risk Women
Author Information
Author(s): Sauter Edward R, Qin Wenyi, Hewett John E, Ruhlen Rachel L, Flynn John T, Rottinghaus George, Chen Yin-Chieh
Primary Institution: University of Missouri
Hypothesis
Circulating concentrations of celecoxib influence PGE2 response, and plasma levels of the drug are influenced by menopausal status.
Conclusion
In high risk women taking 400 mg celecoxib twice daily, plasma concentrations of celecoxib correlated with downregulation of PGE2 production by breast tissue.
Supporting Evidence
- 400 mg celecoxib significantly decreased PGE2 levels in nipple aspirate fluid.
- Plasma concentrations of celecoxib correlated with the change in NAF PGE2 levels.
- Postmenopausal women showed a significant decrease in NAF PGE2 concentrations.
Takeaway
This study found that taking a higher dose of celecoxib can lower a substance linked to breast cancer in women at high risk.
Methodology
Matched nipple aspirate fluid and plasma were collected from 46 high risk women who took celecoxib for two weeks.
Potential Biases
Potential bias due to self-reported compliance and side effects.
Limitations
The study had a small sample size and focused only on high risk women.
Participant Demographics
Women aged 23-81, primarily Caucasian, with a mix of premenopausal and postmenopausal participants.
Statistical Information
P-Value
0.03
Statistical Significance
p = 0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website